APO-QUINAPRIL quinapril 10mg (as hydrochloride) tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-quinapril quinapril 10mg (as hydrochloride) tablets blister pack

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; crospovidone; povidone; colloidal anhydrous silica; calcium sulfate dihydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

QUINAPRIL GENERIC HEALTH quinapril 20mg (as hydrochloride) tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

quinapril generic health quinapril 20mg (as hydrochloride) tablets blister pack

generic health pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; magnesium carbonate hydrate; colloidal anhydrous silica; povidone; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

QUINAPRIL GENERIC HEALTH quinapril 10mg (as hydrochloride) tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

quinapril generic health quinapril 10mg (as hydrochloride) tablets blister pack

generic health pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; crospovidone; colloidal anhydrous silica; povidone; magnesium stearate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

QUINAPRIL GENERIC HEALTH quinapril 5mg (as hydrochloride) tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

quinapril generic health quinapril 5mg (as hydrochloride) tablets blister pack

generic health pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; crospovidone; calcium sulfate dihydrate; magnesium stearate; magnesium carbonate hydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

PERINDOPRIL GENERICHEALTH perindopril erbumine 8mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

perindopril generichealth perindopril erbumine 8mg tablet blister pack

lupin australia pty limited - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; silica dimethyl silylate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

PERINDOPRIL GENERICHEALTH perindopril erbumine 4mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

perindopril generichealth perindopril erbumine 4mg tablet blister pack

lupin australia pty limited - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; lactose monohydrate; microcrystalline cellulose; magnesium stearate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

PERINDOPRIL GENERICHEALTH perindopril erbumine 2mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

perindopril generichealth perindopril erbumine 2mg tablet blister pack

lupin australia pty limited - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; magnesium stearate; microcrystalline cellulose; lactose monohydrate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

INDOPRIL 8 perindopril erbumine 8mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

indopril 8 perindopril erbumine 8mg tablet blister pack

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; silica dimethyl silylate; microcrystalline cellulose; magnesium stearate - indopril 8 is indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that indopril 8 be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

INDOPRIL 4 perindopril erbumine 4mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

indopril 4 perindopril erbumine 4mg tablet blister pack

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; silica dimethyl silylate; lactose monohydrate - indopril 4 is indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that indopril 4 be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

INDOPRIL 2 perindopril erbumine 2mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

indopril 2 perindopril erbumine 2mg tablet blister pack

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; silica dimethyl silylate - indopril 2 is indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that indopril 2 be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.